Immunotherapy Increases Survival of Melanoma Brain Metastases Patients

Melanoma, a form of skin cancer, accounts for about 1% of all skin cancer cases and a vast majority of skin cancer deaths. In Stage IV melanoma more than 60% of patients will develop brain metastases, which is difficult to treat and carries an overall survival of about 4-5 months. A recent study out of Boston, MA looked at checkpoint blockade immunotherapies in the treatment of melanoma brain metastases. Melanoma, a form of skin cancer, accounts for about 1% of all skin cancer cases and a vast majority of skin cancer deaths. In Stage IV melanoma more than 60% of patients will develop brain metastases, which is difficult to treat and carries an overall survival of about 4-5 months. A recent study out of Boston, MA looked at checkpoint blockade immunotherapies in the treatment of melanoma brain metastases.